- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
High-alert therapy area: The MS DMT landscape generates frequent PMCPA complaints about comparative efficacy claims. Psychiatric medicines carry additional risks around patient vulnerability, social media content and prescribing practice suggestions. Alzheimer's disease treatments face intense scrutiny around cognitive decline and quality-of-life claims.
Indirect comparisons between natalizumab, ocrelizumab, ofatumumab, siponimod and other DMTs — particularly regarding relapse rates, disability progression or brain volume loss — regularly result in PMCPA complaints when the underlying data does not support direct comparison.
Alzheimer's disease treatment materials that overstate cognitive benefit, imply disease modification without robust evidence or use quality-of-life measures selectively are a high-risk area given patient vulnerability and family/carer scrutiny.
Promotional content about antidepressants, antipsychotics or mental health conditions on social media — including branded accounts, patient community support pages and influencer partnerships — requires careful management given vulnerability considerations.
MS patient support programmes and psychiatric nurse educator services must not cross into promotion. The PMCPA has repeatedly found that educational programmes around injectable MS therapies blurred this boundary.
Promotional materials that imply specific prescribing patterns — particularly around long-term use, tapering or as-needed dosing for psychiatric medicines — without licenced indication support have attracted regulatory challenge.
Off-label use of antipsychotics and antidepressants is common in clinical practice, but any promotional suggestion of off-label use — even indirect — is a serious Code breach that has resulted in high-profile PMCPA proceedings.
Built specifically for pharma teams working in CNS and neurology — not generic compliance content repurposed for your therapy area.
The pack includes expert walkthroughs of all relevant PMCPA adjudications in CNS and neurology. Here are three landmark cases.
The pack includes all relevant CNS & neurology PMCPA cases with video walkthroughs, expert commentary and quiz questions.
MSLs and medical advisors presenting MS DMT data, supporting HCP education on neurodegeneration and managing off-label enquiries in psychiatry and neurology
Sales specialists and brand managers responsible for MS, Alzheimer's and psychiatric medicine promotional materials, digital campaigns and HCP communications
Teams managing patient support programmes, MS nurse relationships and digital patient communities where the boundary between support and promotion must be carefully maintained
Regulatory affairs and compliance officers reviewing CNS promotional materials, social media content and patient support programme activities for ABPI Code compliance
Speak to us about the CNS & Neurology Compliance Pack. Tell us your team size and therapy area focus and we'll put together the right package.
Need more therapy areas? See all 12 therapy area packs →
JAK inhibitors, TNF inhibitors, IL-17/23 inhibitors. Biosimilar claims, safety label changes and indication creep.
All 2,000+ PMCPA cases. Video. Podcast. Quiz. 5 points per case. The only case library of its kind in the UK.
12 therapy area packs covering Respiratory, Oncology, Cardiovascular, CNS, Diabetes, Immunology, Infectious Diseases, Dermatology, Musculoskeletal, Ophthalmology and more.
One real case. One key lesson. Every week — free.